Inotuzumab Ozogamicin (IO)

DRUG4 trials

Sponsors

Gruppo Italiano Malattie EMatologiche dell'Adulto, Institute of Hematology & Blood Diseases Hospital, China, PETHEMA Foundation

Conditions

Acute Lymphobkastic LeukemiaAcute Lymphoid LeukemiaAdultPh+ Acute Lymphoblastic Leukemia (Ph+ALL)Ph- Acute Lymphoblastic Leukemia (Ph-ALL)

Phase 2

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Active, not recruitingNCT03610438

Gruppo Italiano Malattie EMatologiche dell'AdultoAcute Lymphoid Leukemia

Start: 2019-10-30End: 2026-10-01Target: 76Updated: 2026-07-16

Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

Not yet recruitingNCT07643103

Institute of Hematology & Blood Diseases Hospital, ChinaPh- Acute Lymphoblastic Leukemia (Ph-ALL)

Start: 2026-06-12End: 2030-05-31Target: 32Updated: 2026-06-11

Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL

Not yet recruitingNCT07840976

Institute of Hematology & Blood Diseases Hospital, ChinaPh+ Acute Lymphoblastic Leukemia (Ph+ALL)

Start: 2026-10-12End: 2030-05-31Target: 22Updated: 2026-09-25

Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia

Not yet recruitingNCT07862946

PETHEMA FoundationAcute Lymphobkastic Leukemia, Adult

Start: 2026-10-30End: 2030-10-30Target: 30Updated: 2026-10-07

Related Papers

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood2022-11-1511 citations